|
The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL—Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study. |
| |
|
|
|
Stock and Other Ownership Interests - GRYT Health |
Research Funding - Amgen (Inst); Pfizer (Inst); Seagen (Inst); Syneos Health (Inst) |
| |
|
Honoraria - Abbvie/Pharmacyclics; Cota Healthcare; Curio Science; Epizyme; HMP; HUTCHMED; Incyte; Miltenyi Biotec; MorphoSys; Novartis; OncLive Clinical Congress Consultants; Patient Power; PER; Pharmacyclics; Research to Practice; Seagen; Takeda; Targeted Oncology; WebMD |
Consulting or Advisory Role - Abbvie; Cota Healthcare; Epizyme; Incyte; Miltenyi Biotec; MorphoSys; Novartis; Pharmacyclics; Seagen |
Speakers' Bureau - Curio Science; Research to Practice |
Travel, Accommodations, Expenses - Curio Science; Novartis; Seagen |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Seagen |
| |
|
|
Research Funding - Seagen (Inst); Syneos Health (Inst) |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Seagen |
| |
|
|
| |
|
Employment - Genesis Research |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Seagen |